Over the past 5 years, addition of bevacizumab to combination chemotherapy for advanced, recurrent, and persistent cervical cancer has offered prolonged overall and progression-free survival. Since the original press release announcing the survival benefits of this antiangiogenesis therapy, there has been further study of bevacizumab related to quality of life, combination with other agents, use of imaging to evaluate likelihood of response, and development of biosimilars. This review summarizes publications related to bevacizumab use in advanced, recurrent, and persistent cervical cancer over the past 5 years since initial proof of concept of antiangiogenesis therapy and the initial dissemination of information regarding survival benefits of bevacizumab.

Purpose of review With a worldwide increase in obesity, there has been an increase in obesity-related diseases. Endometrial cancer is a common cause of cancer for women worldwide. Incidence of endometrial cancer has risen worldwide. Accompanying these patients are risk factors and challenges that may prevent standard of care from being delivered. Recent findings The current article describes recent literature describing surgical approaches to the obese patient and special considerations in this population. This article also reviews bariatric surgery and endometrial cancer as well as new updates in radiation, chemotherapy and hormonal therapy research in the obese population. Summary The current article reviews therapeutics and surgery in the morbidly obese for the treatment of endometrial cancer.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZEJULA safely and effectively. See full prescribing information for ZEJULA. ZEJULA TM (niraparib) capsules, for oral use Initial U.S. Approval: 2017 INDICATIONS AND USAGE ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. (1) DOSAGE AND ADMINISTRATION  Recommended dose is 300 mg taken once daily with or without food. (2.1)  Continue treatment until disease progression or unacceptable adverse reaction. (2.1, 2.2)  For adverse reactions, consider interruption of treatment, dose reduction, or dose discontinuation. (2.2) DOSAGE FORMS AND STRENGTHS Capsules: 100 mg (3) CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS  Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): MDS/AML occurred in patients exposed to ZEJULA, and some cases were fatal. Monitor patients for hematological toxicity and discontinue if MDS/AML is confirmed (5.1)  Bone Marrow Suppression: Test complete blood counts weekly for the first month, monthly for the next 11 months and periodically thereafter for clinically significant changes. (5.2)  Cardiovascular Effects: Monitor blood pressure and heart rate monthly for the first year and periodically thereafter during treatment with ZEJULA. Manage with antihypertensive medications as well as adjustment of the ZEJULA dose, if necessary. (5.3)  Embryo-Fetal Toxicity: ZEJULA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.4, 8.1, 8.3) ADVERSE REACTIONS Most common adverse reactions (incidence ≥10%) are thrombocytopenia,

Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.